IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers? ⬆️IL-22 in AxSpA vs. controls ⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP Abs#385 #ACR21 @RheumNow https://t.co/hNtStAluJH

#ACR21 #Abstr0189 Another case for early intervention. Median time-to-Rilonacept (IL1-i) monotherapy for recurrent pericarditis was 7.9 weeks! During this time, >94% pts discontinued steroid and/or colchicine either sequentially or concurrently @RheumNow https://t.co/ofi3Jtm6j6 https://t.co/b6PnFw4gUN

• Tapering and Discontinuation of Background Therapies During the Transition to R…

Active RA w/ large joint swelling & co-existent CVD & diabetes associated with ⬆️risk of #AlzheimersDisease & related #dementia in RA pts. 👉~1300 patients 👉Among CVD conditions, #stroke & #CHF assoc w/ the risk of #dementia #ACR21 Abs#0284 @RheumNow https://t.co/N3x2ZtBFGe https://t.co/kFyf3A0gha

• Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Pop…

Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment ⬆️ACR20 response compared to pbo ⬆️secondary endpoints ⭐️no new safety signals Abs#453 #ACR21 #ACRBest @RheumNow https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5

• Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Int…

Abs 457 #ACR21 @rheumnow Exciting work by @alhkim and colleagues on SARS-CoV-2 Vaccination in CID patients - Most (90%) developed Ab response but with reduced titers - GC users including some low dose mounted low responses - TNFi reduced in vitro neutralization of delta variant https://t.co/fJxnKmbccc

Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?

2 year study of AxSpA pts in clinical remission who tapered TNFi. ⭐️52% successfully tapered to either 2/3, 1/2 or 1/3 dose ⭐️Baseline physician global score independent predictor of successful tapering Abs#364 #ACR21 @RheumNow https://t.co/9Kti5JGMYr https://t.co/y1Uj2dTABC

• Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Rou…

In a newly diagnosed SLE patient with class IV nephritis, already on HCQ, in addition to GC's, would you... #ACR21 #GreatDebate @rheumnow #LupusNephritis

#ACR21 #ACRBest @Rheumnow Abst #0452 Raychaudhuri et al. TB-PET/CT indices ➡️ disease outcome measures in PsA Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS

@ericdeinmd @RheumNow *TICOSPA IMO, more an issue of poor tools for activity monitoring and insufficiently diverse toolbox. Works in RA as lots of choices and good activity measures. Until AxSpa has those, don’t see how we hope to meet “tight control”.

@RheumNow #acr21 abst 195 prospective study of JAKi for refractory Still’s in 7 pts suggests JAKs can be useful as an add on but not in monotherapy : partial response 57%& failure in43%. No patient achieved complete remission. steroids could be decreased by63%~ https://t.co/rYHVReRHvL

Irish registry of AS pts included 76 women who were pregnant ⭐️58% uncomplicated, 41.9% complicated, 11% multiple complications ⭐️frequency of miscarriage ⬆️ ⭐️complications included C-section, preterm, NICU admission #ACR21 @RheumNow Abs#369 https://t.co/90dolEeTIw

#ClinicalPearl. During Q&A of abst#0457 Kim A, et al plenary at #ACR2021 #ACR21 Dr Kim said with 3rd #COVIDvaccination dose the pts who had little or no response to spike protein DID mount a response. 3rd dose in vulnerable pts works #ACRBest @RheumNow

Secondary antiphospholipid syndrome (2APS) in SLE in Georgia Registry 👉12-14% of SLE pts 👉aCL 67%, LAC 51.5%, and aB2GP 7.7% 👉Inc rates of +dsDNA/Smith, livedo reticularis, serositis, & heme/renal/neuro d/o 👉⬇️rate in Black pts, but ⬆️thrombosis #ACR21 Abs 0078 @RheumNow